URI alleviates tyrosine kinase inhibitors-induced ferroptosis by reprogramming lipid metabolism in p53 wild-type liver cancers.

Autor: Ding, Zhiwen, Pan, Yufei, Shang, Taiyu, Jiang, Tianyi, Lin, Yunkai, Yang, Chun, Pang, Shujie, Cui, Xiaowen, Wang, Yixiu, Feng, Xiao fan, Xu, Mengyou, Pei, Mengmiao, Chen, Yibin, Li, Xin, Ding, Jin, Tan, Yexiong, Wang, Hongyang, Dong, Liwei, Wang, Lu
Předmět:
Zdroj: Nature Communications; 10/7/2023, Vol. 14 Issue 1, p1-20, 20p
Abstrakt: The clinical benefit of tyrosine kinase inhibitors (TKIs)-based systemic therapy for advanced hepatocellular carcinoma (HCC) is limited due to drug resistance. Here, we uncover that lipid metabolism reprogramming mediated by unconventional prefoldin RPB5 interactor (URI) endows HCC with resistance to TKIs-induced ferroptosis. Mechanistically, URI directly interacts with TRIM28 and promotes p53 ubiquitination and degradation in a TRIM28-MDM2 dependent manner. Importantly, p53 binds to the promoter of stearoyl-CoA desaturase 1 (SCD1) and represses its transcription. High expression of URI is correlated with high level of SCD1 and their synergetic expression predicts poor prognosis and TKIs resistance in HCC. The combination of SCD1 inhibitor aramchol and deuterated sorafenib derivative donafenib displays promising anti-tumor effects in p53-wild type HCC patient-derived organoids and xenografted tumors. This combination therapy has potential clinical benefits for the patients with advanced HCC who have wild-type p53 and high levels of URI/SCD1. Despite being a promising treatment for hepatocellular carcinoma (HCC), resistance to tyrosine kinase inhibitors (TKI) present a major obstacle. Here, the authors demonstrate that lipid metabolism reprogramming via URI mediated stearoyl-CoA desaturase 1 upregulation present a targetable driver of sorafenib resistance in HCC. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: